title: Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.
abstract: Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.
authors.affiliation: Melanoma Institute Australia; Sydney, NSW Australia ; University of Sydney; Sydney, NSW Australia.
authors.forename: James S
authors.initials: JS
authors.lastname: Wilmott
authors.forename: Richard A
authors.initials: RA
authors.lastname: Scolyer
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
authors.forename: Peter
authors.initials: P
authors.lastname: Hersey